Welcome to our dedicated page for Mineralys Therapeutics news (Ticker: MLYS), a resource for investors and traders seeking the latest updates and insights on Mineralys Therapeutics stock.
Mineralys Therapeutics, Inc. (Nasdaq: MLYS) is a clinical-stage biopharmaceutical company developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Company news frequently centers on clinical trial milestones, regulatory interactions and scientific recognition related to hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other conditions driven by dysregulated aldosterone.
News updates from Mineralys describe progress across a broad clinical program. These include topline and subgroup results from the pivotal Launch-HTN Phase 3 trial in uncontrolled or treatment-resistant hypertension, data from the Advance-HTN trial, and long-term follow-up in the Transform-HTN open-label extension. Additional coverage highlights Phase 2 studies such as Explore-CKD, which evaluated lorundrostat in participants with hypertension, CKD and albuminuria, and Explore-OSA, a trial in overweight or obese adults with moderate-to-severe OSA and hypertension.
Investors and observers can also find announcements about regulatory steps, such as plans for and filing of a New Drug Application (NDA) for lorundrostat with the U.S. Food and Drug Administration, as well as public equity offerings and other financing activities disclosed in SEC filings and press releases. Mineralys regularly reports on participation in major medical and scientific meetings, where data from Launch-HTN and Explore-CKD have been featured in sessions and roundups by organizations such as the American Society of Nephrology and the Journal of the American Medical Association.
This news feed aggregates these developments so readers can follow Mineralys Therapeutics’ clinical, regulatory, financial and corporate communications over time, with a particular focus on the evolving evidence base for lorundrostat in hypertension and related comorbidities.
Mineralys Therapeutics (NASDAQ: MLYS) has scheduled a conference call and webinar for March 10, 2025, at 8:00 AM ET to announce topline results from two pivotal trials: Launch-HTN and Advance-HTN.
The trials evaluated lorundrostat, a highly selective aldosterone inhibitor, for treating uncontrolled hypertension (uHTN) or resistant hypertension (rHTN). The Launch-HTN trial tested lorundrostat as an add-on therapy to existing prescribed background treatment of 2-5 antihypertensive medications, while Advance-HTN evaluated it as an add-on to a standardized background treatment of 2-3 anti-hypertensive medications.
Mineralys Therapeutics (NASDAQ: MLYS) reported its Q4 and full-year 2024 financial results, highlighting significant progress in its clinical development programs. The company anticipates topline data from two pivotal trials: Advance-HTN in March 2025 and Launch-HTN in mid-first half of 2025, both evaluating lorundrostat for uncontrolled or resistant hypertension.
Financial highlights include cash position of $198.2 million as of December 31, 2024, expected to fund operations through Q1 2026. R&D expenses increased to $168.6 million for 2024, up from $70.4 million in 2023. The company reported a net loss of $177.8 million for 2024, compared to $71.9 million in 2023.
The company completed enrollment in the Explore-CKD Phase 2 trial with data expected in Q2 2025 and plans to initiate a Phase 2 trial for obstructive sleep apnea and hypertension in Q1 2025.
Mineralys Therapeutics (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines for hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other aldosterone-related diseases, has scheduled its fourth quarter and full year 2024 financial results announcement. The results will be released before market open on Wednesday, February 12, 2025.
The company will host a conference call at 8:30 a.m. ET on the same day, accessible via domestic (1-800-717-1738) and international (1-646-307-1865) dial-in numbers. A live webcast will be available through the Investor Relations section of the company's website.
Mineralys Therapeutics (NASDAQ: MLYS) has completed enrollment in its Explore-CKD Phase 2 trial, evaluating lorundrostat for treating hypertension in patients with Stage 2 to 3b CKD and albuminuria. The trial focuses on patients already receiving stable treatment with ACEi or ARB and SGLT2 inhibitors.
The study is designed as a randomized, double-blind, placebo-controlled, two-period, two-sequence crossover trial, testing 25 mg once-daily lorundrostat. The primary endpoint measures change in systolic blood pressure at week four compared to placebo, with an exploratory endpoint examining changes in urine albumin-to-creatinine ratio.
The company expects to announce topline data in Q2 2025. This marks Mineralys's third trial to complete enrollment, alongside Target-HTN, Advance-HTN, and the recently announced Explore-OSA trials.
Mineralys Therapeutics (NASDAQ: MLYS) has received FDA clearance for its IND Application to conduct a Phase 2 clinical trial evaluating lorundrostat in treating patients with moderate-to-severe obstructive sleep apnea (OSA) and hypertension. The trial is set to begin in Q1 2025.
The planned study will be placebo-controlled and crossover-designed, testing lorundrostat 50mg once daily in approximately 40 subjects across 40 sites. Participants must be at least 18 years old with a BMI ≥27 kg/m2. The trial aims to validate lorundrostat's ability to reduce upper airway obstruction and nocturnal hypertension, with the primary outcome measuring changes in apnea-hypopnea episodes.
OSA represents Mineralys' third targeted indication for lorundrostat, affecting an estimated 54 million people in the U.S., including 30-50% of adults with hypertension. The company confirms sufficient funding through Q1 2026 to support planned clinical trials and operations.
Mineralys Therapeutics (NASDAQ: MLYS) announced completion of enrollment in two pivotal trials for lorundrostat, targeting uncontrolled and resistant hypertension. The company expects topline data from Advance-HTN trial in March 2025 and Launch-HTN Phase 3 trial in mid-first half 2025. Enrollment continues in the Explore-CKD Phase 2 trial, with data expected in Q2 2025.
Financial highlights show cash position of $263.6 million as of September 30, 2024. R&D expenses increased to $54.0 million from $22.5 million year-over-year. Net loss widened to $56.3 million compared to $22.8 million in Q3 2023.
Mineralys Therapeutics (NASDAQ: MLYS), a clinical-stage biopharmaceutical company specializing in treatments for hypertension and chronic kidney disease, has announced its participation in three upcoming investor conferences. The company will engage in fireside chats at the Guggenheim Healthcare Innovation Conference (November 12, 4:00pm EST), Stifel Healthcare Conference (November 19, 10:20am EST), and Evercore ISI HealthCONx Conference (December 4, 4:15pm EST). Live webcasts will be available on the company's website under the Investor Relations section, with replays accessible for approximately 90 days.
Mineralys Therapeutics (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines for hypertension, chronic kidney disease and aldosterone-related disorders, has scheduled its Q3 2024 financial results announcement for November 11, 2024, after market close. The company will host a conference call at 4:30 p.m. ET on the same day, accessible via domestic (1-877-407-9127) and international (1-201-689-8574) dial-in numbers. A live webcast will be available through the company's Investor Relations website.
Mineralys Therapeutics (NASDAQ: MLYS) has completed enrollment ahead of schedule for Launch-HTN, the second pivotal trial evaluating lorundrostat for uncontrolled and resistant hypertension treatment. The trial's topline data is now expected in mid-first half of 2025, earlier than initially planned.
Launch-HTN is a global, randomized, double-blinded, placebo-controlled Phase 3 trial enrolling adults who failed to achieve blood pressure goals despite taking 2-5 antihypertensive medications. Participants were randomized into three groups: placebo, lorundrostat 50mg daily, and lorundrostat 50mg daily with potential titration to 100mg at week six.
Mineralys Therapeutics (Nasdaq: MLYS) will host a virtual KOL event on October 30, 2024, at 10:00 AM ET to discuss the unmet medical need in uncontrolled and resistant hypertension and the potential of lorundrostat as a treatment. The event will feature experts including Luke J. Laffin, MD (Cleveland Clinic), James M. Luther, MD, MSCI (Vanderbilt University Medical Center), and Rhian Touyz, MBBCh, MSc (Med), PhD (McGill University Health Centre). Topics will include the ongoing Advance-HTN and Launch-HTN pivotal trials, as well as results from the Phase 2 Target-HTN proof-of-concept trial. A live Q&A session will follow.
FAQ
What is the current stock price of Mineralys Therapeutics (MLYS)?
What is the market cap of Mineralys Therapeutics (MLYS)?
